TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06627582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMIS Scale v2.0 - Pain Intensity 3a
Description: PROMIS Scale v2.0 - Pain Intensity 3a is a 3-question short form in which patients rate their worst, average, and current level of pain during the past 7 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMIS 29+2
Description: PROMIS 29+2 (PROMIS-Preference, PROPr) is a compilation of item banks to assess pain intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMIS Scale v2.0 - Nociceptive Pain Quality 5a
Description: 5-question short form that identifies patients who have experienced nociceptive pain during the past 7 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMIS Scale v2.0 - Neuropathic Pain Quality 5a
Description: 5-question short form that identifies patients who have experienced neuropathic pain during the past 7 days
Study: NCT06622148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)
Description: For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)
Description: For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
Study: NCT06693817

Intervention type: DEVICE
Group type: OTHER
Intervention: Wireless skin sensors vital sign monitoring system
Description: The wireless monitoring system will be applied to the newborn and consist of a chest sensor (Anne Arc by Sibel Inc.) and a RAD-7 (Masimo)pulse oximeter limb sensor.

Intervention type: DEVICE
Group type: OTHER
Intervention: Wireless skin sensors vital sign monitoring system
Description: The wireless monitoring system will be applied to the newborn and consist of a chest sensor (Anne Arc by Sibel Inc.) and a RAD-7 (Masimo)pulse oximeter limb sensor.

Intervention type: DEVICE
Group type: OTHER
Intervention: Wired vital sign monitoring system
Description: A standard ECG and SpO2 monitoring device will be applied suing the Infinity M540 monitor (Draeger, Germany). The chest sensor will be placed as per standard of care on the newborn's chest and abdomen, and the SpO2 sensor on their hands or feet.

Intervention type: DEVICE
Group type: OTHER
Intervention: Wired vital sign monitoring system
Description: A standard ECG and SpO2 monitoring device will be applied suing the Infinity M540 monitor (Draeger, Germany). The chest sensor will be placed as per standard of care on the newborn's chest and abdomen, and the SpO2 sensor on their hands or feet.
Study: NCT06632015

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root canal treatment and intracanal medicament
Description: Root canal treatment and intracanal medicament procedures explained in arm descriptions.
Study: NCT06176755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training with weighted ankle cuffs
Description: Group A: Treadmill training and Ankle cuff.~Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Treadmill training only
Study: NCT05445076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-TRBV9 monoclonal antibody, low dose
Description: infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: anti-TRBV9 monoclonal antibody, low dose
Description: infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-TRBV9 monoclonal antibody, high dose
Description: infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion
Study: NCT06632015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal treatment and intracanal medicament
Description: Root canal treatment and intracanal medicament procedures explained in arm descriptions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal treatment and intracanal medicament
Description: Root canal treatment and intracanal medicament procedures explained in arm descriptions.
Study: NCT06629610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DAiLY
Description: The 2-year intervention includes three components, all supported by social media. Home-Based Workshops will be delivered by community members to increase knowledge and skills related to food choices, and to emphasize the importance of physical activity. Emphasis is placed on the benefits of consuming subsistence foods, as well as healthy store-bought foods. Food store modifications will increase access to healthy foods in local stores by working with store managers to stock and promote affordable healthy foods, and will provide participants with opportunities to implement what they have learned in HBWs. Point of purchase promotions, educational displays, taste tests and cooking demonstrations, will identify and promote these foods to community members. Physical activity promotion will include community-wide traditional activities, such as traditional dance, sports events, and berry festivals. Fitbits will be used as a motivational tool for participants to track their progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DAiLY
Description: The 2-year intervention includes three components, all supported by social media. Home-Based Workshops will be delivered by community members to increase knowledge and skills related to food choices, and to emphasize the importance of physical activity. Emphasis is placed on the benefits of consuming subsistence foods, as well as healthy store-bought foods. Food store modifications will increase access to healthy foods in local stores by working with store managers to stock and promote affordable healthy foods, and will provide participants with opportunities to implement what they have learned in HBWs. Point of purchase promotions, educational displays, taste tests and cooking demonstrations, will identify and promote these foods to community members. Physical activity promotion will include community-wide traditional activities, such as traditional dance, sports events, and berry festivals. Fitbits will be used as a motivational tool for participants to track their progress.
Study: NCT06630221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG)
Description: 100 mg, 28-day cycles, 3+ cycles
Study: NCT06628882

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular Block
Description: types of anesthesia used in upper extremity surgeries

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide-Awake Local Anesthesia with No Tourniquet
Description: types of anesthesia used in upper extremity surgeries
Study: NCT06630559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P55
Description: CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P55
Description: CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Cosentyx
Description: European Union (EU)-approved Cosentyx, 300 mg by 2 SC injections of 150 mg/mL via PFS every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by Q4W for 11 doses (up to Week 48).
Study: NCT06629428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: The participants will receive 48 weeks of treatment with ublituximab.
Study: NCT06629493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit Versa 3
Description: Fitbit Versa 3 is a commercially available activity tracker

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-patient alcohol use disorder treatment
Description: In-patient alcohol use disorder treatment, including group therapy, counseling, and occupational activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-patient alcohol use disorder treatment
Description: In-patient alcohol use disorder treatment, including group therapy, counseling, and occupational activities
Study: NCT05423587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genicular Artery Embolisation
Description: Transarterial catheter directed embolisation of hypervascularity in patients with mild to moderate knee osteoarthritis
Study: NCT05517525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet.
Study: NCT05423587

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Genicular Artery Injection
Description: Transarterial catheter directed injection of normal (0.9%) saline in patients with mild to moderate knee osteoarthritis
Study: NCT06698367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: Protocol based on the best available evidence and to be used in all participants in both groups. The standard rehabilitation protocol will consist of three postoperative phases: Mobilization (0 to 4 weeks), Strengthening (4 to 8 weeks) and Functional phase (8 to 12 weeks). Sessions will be held 3 times a week for 12 weeks. Each session will last 1 hour and will consist of different modalities of therapeutic exercise and cryotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Protocol based on the best available evidence and to be used in all participants in both groups. The standard rehabilitation protocol will consist of three postoperative phases: Mobilization (0 to 4 weeks), Strengthening (4 to 8 weeks) and Functional phase (8 to 12 weeks). Sessions will be held 3 times a week for 12 weeks. Each session will last 1 hour and will consist of different modalities of therapeutic exercise and cryotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral high-intensity strength exercise
Description: Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an eccentric exercise for the pronosupinator muscles with a dumbbell with adjustable weights. The training will start with an intensity of 60% of 1RM, until reaching 80% 1RM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral mobility exercises
Description: Participants will be seated in an armchair with armrests and will perform 4 sets of 8 repetitions of an active mobility exercise for the pronation-supination muscles using a plastic rod.
Study: NCT06700928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External focus training
Description: External focus training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal focus training
Description: internal focus training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No attentional focus training
Description: no attentional focus training
Study: NCT06703424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-cycling
Description: Sit-cycling for 5 mins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stand-twisting
Description: Stand-twisting for 5 mins
Study: NCT06711991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3927 powder for inhalation
Description: TQC3927 is a targeted inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQC3927 powder for inhalation placebo
Description: A placebo without drug substance.
Study: NCT06714617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M17D1
Description: The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 via by intravenous infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M17D1
Description: The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 via by intravenous infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M17D1
Description: The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 via by intravenous infusion every 3 weeks.
Study: NCT06713096

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tempos Certos protocol
Description: Improve the enhanced recovery by using the Tempos Certos Protocol by the multiprofissional team , using interventions known by science and recommended by scientists.
Study: NCT06711094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib: 125mg orally, with a treatment cycle every 28 days, with continuous administration for the first 3 weeks (days 1 to 21) and rest (no medication) for the second 1 week (days 22 to 28). It is recommended to take Dalpiciclib at about the same time every day.~Albumin-bound paclitaxel for injection: 125mg/m2, intravenous infusion for 30 minutes, D1, D8, every 28 days for a treatment cycle, at least ≥6 treatment courses.~Endocrine therapy: Endocrine therapy drugs are selected by the investigator
Study: NCT06712511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine content
Description: Participants will drink the same volume of water or coffee, caffeine content is 2mg/kg by body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine content
Description: Participants will drink the same volume of water or coffee, caffeine content is 2mg/kg by body weight.
Study: NCT06711003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enhanced external counterpulsation
Description: Enhanced External Counterpulsation (EECP) is a non-invasive treatment primarily used for patients with angina or heart failure. It involves the application of pressure cuffs to the legs, which inflate and deflate in sync with the cardiac cycle. This enhances blood flow to the heart during diastole, the phase when the heart is resting between beats. The increased pressure promotes coronary artery perfusion, helping to improve oxygen delivery to the heart muscle, reduce angina symptoms, and enhance cardiovascular function. EECP is typically recommended for patients who are not good candidates for invasive procedures like angioplasty or bypass surgery, or for those seeking supplementary treatment for angina. Over time, it may promote the development of new blood vessels (collateral circulation), further improving heart health. The treatment is generally administered over several weeks in outpatient settings, with each session lasting around one hour.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post acute care
Description: Post-Acute Care (PAC) for stroke patients focuses on improving functional independence, reducing disability, and preventing secondary complications.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post acute care
Description: Post-Acute Care (PAC) for stroke patients focuses on improving functional independence, reducing disability, and preventing secondary complications.
Study: NCT06710405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine (drug)
Description: a single bolus dose of lidocaine 1.5 mg/kg is administered concurrently with the induction of anesthesia, followed by a continuous infusion of lidocaine at a rate of 1.5 mg/kg/hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion (placebo)
Description: Continuous infusion of normal saline in the same volume as that administered to the lidocaine group.
Study: NCT06714162

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Longevity pill
Description: vitamins and herbs
Study: NCT06711341

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole-body Vibration (WBV) Training
Description: Participants use the Compex Winplate, designed specifically for vibration training. The device is set with a frequency of 30 Hz and an amplitude of 4 mm. Participants perform a total of 5 exercises consisting of static and dynamic squat exercises, with a 30-second rest period between sets and between different exercises. The exercises and progression over the weeks are as follows:~Week 1:~* Static squat with knees flexed at 30° - 2 sets of 30 seconds each~* Dynamic squat with knees flexed between 0-60° - 2 sets of 30 seconds each~* Fingertip-to-sole partial dynamic squat with knees flexed at 30° - 2 sets of 30 seconds each~* Consecutive weight transfer with knees flexed at 45° - 2 sets of 30 seconds each~* Single leg static squat with knees flexed at 30° - 30 seconds per leg~Subsequent Weeks: The duration of each set increases by 10 seconds each week. Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Resistance Exercise (PRE)
Description: Training Duration: Participants undergo approximately 15-20 minute training sessions, 3 days per week for 3 weeks.~Exercise Regimen: The training focuses on strengthening the quadriceps muscles using ankle weights. The load is determined using the DeLorme principle:~* At the beginning of each week, the 10-repetition maximum (10RM) is measured.~* During that week, participants perform their training sets as follows:~  * First set: 50% of 10RM~ * Second set: 75% of 10RM~ * Final set: 100% of 10RM Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Exercise
Description: Protocol: Participants receive a printed document with instructions for home exercises and are instructed on how to perform the exercises.~Training Duration: Sessions are conducted three days per week for 3 weeks.~Exercise Regimen: The exercises include:~* Bilateral Quadriceps Isometric Exercise: Participants lie on their backs with a roll below each knee, pressing for 10-second holds, totaling 20 repetitions.~* Knee Extensions: Participants performed knee extensions while seated, holding each extension for 5 seconds, completing 10 repetitions per leg.~* Knee Range of Motion (ROM) Exercises: Participants lie face down and alternately bend their knees, completing 10 repetitions.~Each training session includes a 5-minute warm-up and a 5-minute cooldown, consisting of joint motion and muscle stretching exercises
Study: NCT06714032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM plus conventional drug
Description: All patients were treated according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM placebo plus conventional drug
Description: All patients were treated according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.
Study: NCT06714409

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VExUS guided decongestion
Description: Treatment team will be provided information about venous organ congestion status.
Study: NCT06714097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI
Description: STRATIF-AI apps will be used as an integral part of the dialogue with patients during thesecondary prevention phase

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: healthy dialogue
Description: Patients allocated to arm 2 will receive only standard secondary prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA
Study: NCT06713798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV
Description: atezolizumab (intravenous 1200mg Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV
Description: atezolizumab (intravenous 1200mg Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV
Description: atezolizumab (intravenous 1200mg Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab 600 mg IV
Description: Tiragolumab (intravenous 600mg Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab 600 mg IV
Description: Tiragolumab (intravenous 600mg Q3W)
Study: NCT06711172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health coaching intervention
Description: The health coaching intervention will consist of seventeen, 30 to 60-minute telehealth sessions that were dispersed over six months. Participants will work closely with a health coach to create a plan for making appropriate lifestyle changes and for accomplishing the clinical recommendations that were received from their comprehensive evaluation at the War Related Illness and Injury Study Center.